187 related articles for article (PubMed ID: 11989626)
1. Structure-based ligand design for flexible proteins: application of new F-DycoBlock.
Zhu J; Fan H; Liu H; Shi Y
J Comput Aided Mol Des; 2001 Nov; 15(11):979-96. PubMed ID: 11989626
[TBL] [Abstract][Full Text] [Related]
2. Design of new selective inhibitors of cyclooxygenase-2 by dynamic assembly of molecular building blocks.
Zhu J; Yu H; Fan H; Liu H; Shi Y
J Comput Aided Mol Des; 2001 May; 15(5):447-63. PubMed ID: 11394738
[TBL] [Abstract][Full Text] [Related]
3. Structure-based ligand design by dynamically assembling molecular building blocks at binding site.
Liu H; Duan Z; Luo Q; Shi Y
Proteins; 1999 Sep; 36(4):462-70. PubMed ID: 10450088
[TBL] [Abstract][Full Text] [Related]
4. QXP: powerful, rapid computer algorithms for structure-based drug design.
McMartin C; Bohacek RS
J Comput Aided Mol Des; 1997 Jul; 11(4):333-44. PubMed ID: 9334900
[TBL] [Abstract][Full Text] [Related]
5. MCSS functionality maps for a flexible protein.
Stultz CM; Karplus M
Proteins; 1999 Dec; 37(4):512-29. PubMed ID: 10651268
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
[TBL] [Abstract][Full Text] [Related]
7. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.
Luong C; Miller A; Barnett J; Chow J; Ramesha C; Browner MF
Nat Struct Biol; 1996 Nov; 3(11):927-33. PubMed ID: 8901870
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase.
Llorens O; Perez JJ; Palomer A; Mauleon D
Bioorg Med Chem Lett; 1999 Oct; 9(19):2779-84. PubMed ID: 10522690
[TBL] [Abstract][Full Text] [Related]
9. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?
Soliva R; Almansa C; Kalko SG; Luque FJ; Orozco M
J Med Chem; 2003 Apr; 46(8):1372-82. PubMed ID: 12672237
[TBL] [Abstract][Full Text] [Related]
10. Computer-aided design of selective COX-2 inhibitors: comparative molecular field analysis, comparative molecular similarity indices analysis, and docking studies of some 1,2-diarylimidazole derivatives.
Desiraju GR; Gopalakrishnan B; Jetti RK; Nagaraju A; Raveendra D; Sarma JA; Sobhia ME; Thilagavathi R
J Med Chem; 2002 Oct; 45(22):4847-57. PubMed ID: 12383010
[TBL] [Abstract][Full Text] [Related]
11. Structural approach for COX-2 inhibition.
Michaux C; Charlier C
Mini Rev Med Chem; 2004 Aug; 4(6):603-15. PubMed ID: 15279594
[TBL] [Abstract][Full Text] [Related]
12. Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).
Pouplana R; Lozano JJ; Ruiz J
J Mol Graph Model; 2002 Jan; 20(4):329-43. PubMed ID: 11858641
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola GF; Pattabhi V; Nagarajan K
Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
[TBL] [Abstract][Full Text] [Related]
14. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.
Gehlhaar DK; Verkhivker GM; Rejto PA; Sherman CJ; Fogel DB; Fogel LJ; Freer ST
Chem Biol; 1995 May; 2(5):317-24. PubMed ID: 9383433
[TBL] [Abstract][Full Text] [Related]
15. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
Meagher KL; Carlson HA
J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.
Liu H; Huang X; Shen J; Luo X; Li M; Xiong B; Chen G; Shen J; Yang Y; Jiang H; Chen K
J Med Chem; 2002 Oct; 45(22):4816-27. PubMed ID: 12383007
[TBL] [Abstract][Full Text] [Related]
17. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
19. Enzyme selectivity of new cyclooxygenase-2/5 lipoxygenase inhibitors using molecular modeling approach.
Kothekar V; Sahi S; Mishra J
Indian J Biochem Biophys; 2000 Apr; 37(2):86-96. PubMed ID: 10983419
[TBL] [Abstract][Full Text] [Related]
20. [Studied on docking of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives with cyclooxygenase].
Zhao LQ; Hu YD; Yuan Y; Zhang T; Zhang SF; Li S
Yao Xue Xue Bao; 2001 Jun; 36(6):415-8. PubMed ID: 12585123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
